An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP
The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop l...
Uloženo v:
| Vydáno v: | BMC infectious diseases Ročník 18; číslo 1; s. 506 - 8 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
05.10.2018
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1471-2334, 1471-2334 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The ongoing transmission of
Mycobacterium (M.) leprae
reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.
The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.
The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of
M. leprae
is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.
The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.
The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). |
|---|---|
| AbstractList | The ongoing transmission of
Mycobacterium (M.) leprae
reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.
The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.
The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of
M. leprae
is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.
The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.
The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80-90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted).The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80-90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). Abstract The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries. The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly. The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists. The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance. The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries. The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly. The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists. The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80–90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance. The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80-90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries. The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries. The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly. The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists. The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80-90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance. The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted). Keywords: Post-exposure prophylaxis, Chemoprophylaxis, Intervention study, Leprosy, Rifampicin, Moxifloxacin, Clarithromycin |
| ArticleNumber | 506 |
| Audience | Academic |
| Author | Mieras, Liesbeth F Saunderson, Paul R Gillini, Laura Smith, W Cairns S van Brakel, Wim H Izumi, Shinzo Taal, Anna T Astari, Linda Scollard, David M Cambau, Emmanuelle Prakoeswa, Cita Rosita S do Nascimento, Dejair Caitano Virmond, Marcos C L Grosset, Jacques Kar, Hemanta K Sturkenboom, Marieke G G |
| Author_xml | – sequence: 1 givenname: Liesbeth F orcidid: 0000-0001-6943-1712 surname: Mieras fullname: Mieras, Liesbeth F email: L.Mieras@Leprastichting.nl organization: Netherlands Leprosy Relief – sequence: 2 givenname: Anna T surname: Taal fullname: Taal, Anna T organization: Netherlands Leprosy Relief – sequence: 3 givenname: Wim H surname: van Brakel fullname: van Brakel, Wim H organization: Netherlands Leprosy Relief – sequence: 4 givenname: Emmanuelle surname: Cambau fullname: Cambau, Emmanuelle organization: National Reference Center for mycobacteria and antimycobacterial resistance – sequence: 5 givenname: Paul R surname: Saunderson fullname: Saunderson, Paul R organization: American Leprosy Missions – sequence: 6 givenname: W Cairns S surname: Smith fullname: Smith, W Cairns S organization: Institute of Applied Health Sciences, University of Aberdeen – sequence: 7 givenname: Cita Rosita S surname: Prakoeswa fullname: Prakoeswa, Cita Rosita S organization: Dermatology Health & Venereology, Faculty of Medicine, Airlangga University – sequence: 8 givenname: Linda surname: Astari fullname: Astari, Linda organization: Dermatology Health & Venereology, Faculty of Medicine, Airlangga University – sequence: 9 givenname: David M surname: Scollard fullname: Scollard, David M organization: National Hansen’s Disease Programs – sequence: 10 givenname: Dejair Caitano surname: do Nascimento fullname: do Nascimento, Dejair Caitano organization: Instituto Lauro de Souza Lima – sequence: 11 givenname: Jacques surname: Grosset fullname: Grosset, Jacques organization: Johns Hopkins University School of Medicine – sequence: 12 givenname: Hemanta K surname: Kar fullname: Kar, Hemanta K organization: Department of Dermatology, Leprosy and STD, Paras Hospitals – sequence: 13 givenname: Shinzo surname: Izumi fullname: Izumi, Shinzo organization: Leprosy Study Group, Institute of Tropical Disease, Airlangga University – sequence: 14 givenname: Laura surname: Gillini fullname: Gillini, Laura organization: Global Leprosy Programme, WHO – sequence: 15 givenname: Marcos C L surname: Virmond fullname: Virmond, Marcos C L organization: Instituto Lauro de Souza Lima – sequence: 16 givenname: Marieke G G surname: Sturkenboom fullname: Sturkenboom, Marieke G G organization: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30290790$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktv1DAUhSNURB_wA9igSGxgkeJXYocF0qhqYaRKrXhtLce-yXiU2FM7QTP_Hg9T2k4FCHlh-_o7x_L1Oc4OnHeQZS8xOsVYVO8iJoLXBcKioAyRgj3JjjDjuCCUsoMH68PsOMYlQpgLUj_LDikiNeI1OsouZi4Ht1BOg8kDdHYAl6uYr3wcC1inaQqQ6wUMfhX8arHp1drGvPUh7yFV4uZ9fn1-_Tx72qo-wovb-ST7dnH-9exTcXn1cX42uyx0KSpWiBK1JdVAVNvqRuiqqZVoiRKMYUapRqg2XBvFgNecQQW6qXjZAKWGsbShJ9l852u8WspVsIMKG-mVlb8KPnRShdHqHqTRRghUU2SYZtC0tcBNyRGlWDUt5iZ5fdh5raZmAKPBjUH1e6b7J84uZOd_yApzWhOeDN7cGgR_M0Ec5WCjhr5XDvwUJcG4EowThBL6-hG69FNwqVWJIqRECeP3VKfSA6xrfbpXb03lrCw5JmX6wESd_oFKw8BgdUpIa1N9T_B2T5CYEdZjp6YY5fzL5_9nr77vs68eNvCuc7_TlQC8A3QKSgzQ3iEYyW2C5S7BMiVYbhMsWdLwRxptRzVav_0D2_9TSXbKmG5xHYT7Hv9d9BN6FQEt |
| CitedBy_id | crossref_primary_10_13181_mji_oa_192962 crossref_primary_10_1016_j_idnow_2022_04_001 crossref_primary_10_1002_jcph_2303 crossref_primary_10_1371_journal_pntd_0013057 crossref_primary_10_1186_s12879_024_09125_2 crossref_primary_10_1007_s13311_021_01153_z crossref_primary_10_7717_peerj_17170 crossref_primary_10_3389_fimmu_2024_1298749 crossref_primary_10_1057_s41271_020_00260_z crossref_primary_10_1186_s12879_019_4649_0 crossref_primary_10_1371_journal_pntd_0009039 crossref_primary_10_3389_fmed_2023_1260375 crossref_primary_10_3389_fmicb_2020_01220 crossref_primary_10_1016_j_cmi_2021_07_032 crossref_primary_10_1111_jdv_15569 crossref_primary_10_3892_br_2021_1464 crossref_primary_10_1016_j_banm_2023_04_017 crossref_primary_10_4103_ijdvl_IJDVL_326_19 crossref_primary_10_1371_journal_pntd_0010972 crossref_primary_10_1080_01932691_2021_1997759 crossref_primary_10_1016_j_clinbiochem_2019_01_007 crossref_primary_10_1186_s40249_020_00774_4 crossref_primary_10_1016_j_berh_2020_101509 crossref_primary_10_2147_RRTM_S190300 crossref_primary_10_1371_journal_pntd_0009667 crossref_primary_10_1016_j_vaccine_2021_10_027 |
| Cites_doi | 10.1017/S0950268803001079 10.1016/S0140-6736(82)92334-0 10.1371/journal.pntd.0002404 10.1086/499278 10.1164/rccm.200201-047OC 10.1136/bmjopen-2016-013633 10.1016/j.ijid.2017.05.003 10.1086/516119 10.1590/S1020-49892009001000009 10.1097/INF.0000000000000260 10.1136/bmj.39500.885752.BE 10.1016/0041-3879(80)90060-4 10.1093/oxfordjournals.bmb.a071952 10.1093/jac/43.suppl_2.91 10.1128/AAC.35.3.579 10.1073/pnas.94.22.12106 10.1053/jinf.2000.0698 10.7883/yoken.63.1 10.1358/dot.2000.36.4.570201 10.1016/j.jaad.2009.05.046 10.1128/AAC.01162-07 10.47276/lr.86.2.142 10.1016/S0140-6736(05)60888-4 10.1016/j.cmi.2018.02.022 10.1136/bmj.1.5803.765 10.1186/s13071-015-1143-4 10.1093/infdis/168.1.188 10.1016/S0140-6736(76)92071-7 10.1128/AAC.42.5.1115 10.4269/ajtmh.1968.17.769 10.1097/00006454-198605000-00049 10.3201/eid2103.141313 10.1128/AAC.44.10.2919-2921.2000 10.1128/AAC.00912-12 10.1371/journal.pntd.0005399 10.1097/inf.0000000000000369 10.1186/1745-6673-1-9 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QL 7T2 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12879-018-3402-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2334 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_dcd880930d4c4ebf981b570331abf17d PMC6173927 A557125178 30290790 10_1186_s12879_018_3402_4 |
| Genre | Journal Article |
| GeographicLocations | Netherlands Nepal India |
| GeographicLocations_xml | – name: Netherlands – name: Nepal – name: India |
| GrantInformation_xml | – fundername: Netherlands Leprosy Relief grantid: none funderid: http://dx.doi.org/10.13039/100010156 – fundername: Netherlands Leprosy Relief grantid: none – fundername: ; grantid: none |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QL 7T2 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c5864-850f53ce2affcb8c6b9a8f2a8441433c009d7cda4e7974e6ecb675be33d44ecb3 |
| IEDL.DBID | RSV |
| ISSN | 1471-2334 |
| IngestDate | Fri Oct 03 12:51:53 EDT 2025 Tue Nov 04 02:05:14 EST 2025 Thu Oct 02 05:50:12 EDT 2025 Sun Nov 30 04:29:07 EST 2025 Tue Nov 11 10:14:10 EST 2025 Tue Nov 04 18:00:59 EST 2025 Thu Nov 13 15:48:45 EST 2025 Thu Nov 13 15:30:54 EST 2025 Thu Jan 02 23:00:54 EST 2025 Sat Nov 29 03:13:55 EST 2025 Tue Nov 18 21:55:10 EST 2025 Sat Sep 06 07:26:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Chemoprophylaxis Intervention study Clarithromycin Rifampicin Leprosy Post-exposure prophylaxis Moxifloxacin |
| Language | English |
| License | Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5864-850f53ce2affcb8c6b9a8f2a8441433c009d7cda4e7974e6ecb675be33d44ecb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-6943-1712 |
| OpenAccessLink | https://link.springer.com/10.1186/s12879-018-3402-4 |
| PMID | 30290790 |
| PQID | 2122504727 |
| PQPubID | 42582 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_dcd880930d4c4ebf981b570331abf17d pubmedcentral_primary_oai_pubmedcentral_nih_gov_6173927 proquest_miscellaneous_2116847200 proquest_journals_2122504727 gale_infotracmisc_A557125178 gale_infotracacademiconefile_A557125178 gale_incontextgauss_ISR_A557125178 gale_incontextgauss_IOV_A557125178 pubmed_primary_30290790 crossref_primary_10_1186_s12879_018_3402_4 crossref_citationtrail_10_1186_s12879_018_3402_4 springer_journals_10_1186_s12879_018_3402_4 |
| PublicationCentury | 2000 |
| PublicationDate | 20181005 |
| PublicationDateYYYYMMDD | 2018-10-05 |
| PublicationDate_xml | – month: 10 year: 2018 text: 20181005 day: 5 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2018 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | B Ji (3402_CR46) 1998; 42 NN Bock (3402_CR24) 2002; 165 FJ Moet (3402_CR8) 2006; 193 SC Poliak (3402_CR37) 1985; 254 D Beyene (3402_CR5) 2003; 131 L Trieu (3402_CR50) 2015; 21 L Gillini (3402_CR15) 2017; 11 JH Xiong (3402_CR47) 1994; 62 MS Bader (3402_CR40) 2013; 88 C Diletto (3402_CR14) 2000; 71 P Steinmann (3402_CR17) 2016 MJ Colston (3402_CR22) 1978; 49 PE Fine (3402_CR7) 1997; 146 CC Shepard (3402_CR20) 1972; 21 D Girling (3402_CR53) 1972; 1 SJ Yawalkar (3402_CR52) 1982; 319 DA Mitchison (3402_CR48) 1984; 40 MW Bratschi (3402_CR6) 2015; 86 SG Kosseifi (3402_CR45) 2006; 1 K Tin (3402_CR13) 1999; 67 IM Rosenthal (3402_CR25) 2012; 56 M Matsuoka (3402_CR11) 2010; 63 RH Gelber (3402_CR35) 1994; 62 CC Shepard (3402_CR28) 1968; 17 DJ Girling (3402_CR54) 1979; 57 JE Burkhardt (3402_CR30) 1997; 25 E von Keutz (3402_CR31) 1999; 43 FJ Moet (3402_CR12) 2008; 336 3402_CR19 3402_CR18 JL Arbiser (3402_CR27) 1995; 32 CM Smith (3402_CR9) 2000; 41 B Ji (3402_CR39) 1993; 168 JA Seddon (3402_CR51) 2014; 33 DJ Blok (3402_CR1) 2015; 8 IA Cree (3402_CR4) 1998; 69 T Barth-Jaeggi (3402_CR16) 2016; 6 E Cambau (3402_CR43) 1997; 349 M Zierski (3402_CR21) 1980; 61 S Flor (3402_CR33) 1989; 87 L Reveiz (3402_CR10) 2009; 26 GL Davis (3402_CR26) 2013; 7 S Bonhoeffer (3402_CR41) 1997; 94 FC Adler-Shohet (3402_CR49) 2014; 33 R Jacobson (3402_CR42) 1976; 308 S Consigny (3402_CR23) 2000; 44 3402_CR2 FEF Pardillo (3402_CR29) 2008; 52 P Xu (3402_CR32) 2017; 60 KK Shaughnessy (3402_CR38) 2010; 62 PA Moise (3402_CR34) 2000; 36 3402_CR44 3402_CR3 B Ji (3402_CR36) 1991; 35 |
| References_xml | – volume: 131 start-page: 841 year: 2003 ident: 3402_CR5 publication-title: Epidemiol Infect doi: 10.1017/S0950268803001079 – volume: 319 start-page: 1199 year: 1982 ident: 3402_CR52 publication-title: Lancet doi: 10.1016/S0140-6736(82)92334-0 – volume: 71 start-page: S21 issue: Suppl year: 2000 ident: 3402_CR14 publication-title: Lepr Rev – volume: 21 start-page: 446 year: 1972 ident: 3402_CR20 publication-title: AmJTropMedHyg – volume: 7 year: 2013 ident: 3402_CR26 publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0002404 – volume: 146 start-page: 91 year: 1997 ident: 3402_CR7 publication-title: AmJEpidemiol – volume: 193 start-page: 346 year: 2006 ident: 3402_CR8 publication-title: J Infect Dis doi: 10.1086/499278 – volume: 165 start-page: 1526 year: 2002 ident: 3402_CR24 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200201-047OC – volume: 6 year: 2016 ident: 3402_CR16 publication-title: BMJ Open doi: 10.1136/bmjopen-2016-013633 – volume: 88 start-page: 25 year: 2013 ident: 3402_CR40 publication-title: Am Fam Physician – volume: 60 start-page: 35 year: 2017 ident: 3402_CR32 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2017.05.003 – volume: 87 start-page: 24S year: 1989 ident: 3402_CR33 publication-title: An overview Am J Med – volume: 25 start-page: 1196 year: 1997 ident: 3402_CR30 publication-title: Clin Infect Dis doi: 10.1086/516119 – volume: 26 start-page: 341 year: 2009 ident: 3402_CR10 publication-title: Pan Am J public Heal doi: 10.1590/S1020-49892009001000009 – volume: 33 start-page: 664 year: 2014 ident: 3402_CR49 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000000260 – volume: 32 start-page: 241 year: 1995 ident: 3402_CR27 publication-title: JAmAcadDermatol – volume: 336 start-page: 761 year: 2008 ident: 3402_CR12 publication-title: BMJ doi: 10.1136/bmj.39500.885752.BE – volume: 61 start-page: 41 year: 1980 ident: 3402_CR21 publication-title: Tubercle doi: 10.1016/0041-3879(80)90060-4 – volume-title: Emerging evidence from the leprosy post-exposure prophylaxis project: an overview. Beijing year: 2016 ident: 3402_CR17 – ident: 3402_CR19 – volume: 40 start-page: 84 year: 1984 ident: 3402_CR48 publication-title: Br Med Bull doi: 10.1093/oxfordjournals.bmb.a071952 – volume: 43 start-page: 91 year: 1999 ident: 3402_CR31 publication-title: J Antimicrob Chemother doi: 10.1093/jac/43.suppl_2.91 – volume: 35 start-page: 579 year: 1991 ident: 3402_CR36 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.35.3.579 – ident: 3402_CR2 – volume: 94 start-page: 12106 year: 1997 ident: 3402_CR41 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.94.22.12106 – volume: 49 start-page: 7 year: 1978 ident: 3402_CR22 publication-title: Lepr Rev – volume: 57 start-page: 45 year: 1979 ident: 3402_CR54 publication-title: Bull World Health Organ – volume: 69 start-page: 112 year: 1998 ident: 3402_CR4 publication-title: Lepr Rev – volume: 41 start-page: 137 year: 2000 ident: 3402_CR9 publication-title: J Infect doi: 10.1053/jinf.2000.0698 – volume: 63 start-page: 1 year: 2010 ident: 3402_CR11 publication-title: Jpn J Infect Dis doi: 10.7883/yoken.63.1 – volume: 36 start-page: 229 year: 2000 ident: 3402_CR34 publication-title: Drugs of Today doi: 10.1358/dot.2000.36.4.570201 – volume: 62 start-page: 315 year: 2010 ident: 3402_CR38 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2009.05.046 – volume: 52 start-page: 3113 year: 2008 ident: 3402_CR29 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01162-07 – ident: 3402_CR18 – volume: 86 start-page: 142 year: 2015 ident: 3402_CR6 publication-title: Lepr Rev doi: 10.47276/lr.86.2.142 – ident: 3402_CR3 – volume: 349 start-page: 103 year: 1997 ident: 3402_CR43 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(05)60888-4 – ident: 3402_CR44 doi: 10.1016/j.cmi.2018.02.022 – volume: 1 start-page: 765 year: 1972 ident: 3402_CR53 publication-title: Br Med J doi: 10.1136/bmj.1.5803.765 – volume: 8 year: 2015 ident: 3402_CR1 publication-title: Parasit Vectors doi: 10.1186/s13071-015-1143-4 – volume: 168 start-page: 188 year: 1993 ident: 3402_CR39 publication-title: J Infect Dis doi: 10.1093/infdis/168.1.188 – volume: 308 start-page: 1304 year: 1976 ident: 3402_CR42 publication-title: Lancet doi: 10.1016/S0140-6736(76)92071-7 – volume: 42 start-page: 1115 year: 1998 ident: 3402_CR46 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.42.5.1115 – volume: 17 start-page: 769 year: 1968 ident: 3402_CR28 publication-title: Initial rate in patients Am J Trop Med Hyg doi: 10.4269/ajtmh.1968.17.769 – volume: 254 start-page: 2930 year: 1985 ident: 3402_CR37 publication-title: JAMA doi: 10.1097/00006454-198605000-00049 – volume: 21 start-page: 500 year: 2015 ident: 3402_CR50 publication-title: Emerg Infect Dis doi: 10.3201/eid2103.141313 – volume: 44 start-page: 2919 year: 2000 ident: 3402_CR23 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.44.10.2919-2921.2000 – volume: 56 start-page: 4331 year: 2012 ident: 3402_CR25 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00912-12 – volume: 67 start-page: S26 year: 1999 ident: 3402_CR13 publication-title: IntJLeprOther MycobactDis. – volume: 11 year: 2017 ident: 3402_CR15 publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0005399 – volume: 33 start-page: 1098 year: 2014 ident: 3402_CR51 publication-title: Pediatr Infect Dis J doi: 10.1097/inf.0000000000000369 – volume: 62 start-page: 568 year: 1994 ident: 3402_CR35 publication-title: IntJLeprOther MycobactDis – volume: 1 start-page: 9 year: 2006 ident: 3402_CR45 publication-title: J Occup Med Toxicol doi: 10.1186/1745-6673-1-9 – volume: 62 start-page: 37 year: 1994 ident: 3402_CR47 publication-title: Int J Lepr Other Mycobact Dis |
| SSID | ssj0017829 |
| Score | 2.399429 |
| SecondaryResourceType | review_article |
| Snippet | The ongoing transmission of
Mycobacterium (M.) leprae
reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct... The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct... Abstract The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 506 |
| SubjectTerms | Adults Analysis Anti-Bacterial Agents - therapeutic use Antibiotics Care and treatment Chemoprophylaxis Children Clarithromycin Clarithromycin - therapeutic use Debate Dermatology Dosage and administration Drug dosages Drug resistance Exposure Fluoroquinolones - therapeutic use Humans Incidence Infectious Diseases Internal Medicine Intervention study Leprosy Leprosy - drug therapy Leprosy - microbiology Leprosy - prevention & control Medical Microbiology Medicine Medicine & Public Health Moxifloxacin Multidrug resistant organisms Netherlands Parasitology Pharmacology Post-exposure prophylaxis Post-Exposure Prophylaxis - methods Prevention Prophylaxis Public health Reduction Rifampicin Rifampin Rifampin - therapeutic use Signs and symptoms Treatment outcome Tropical Medicine Tuberculosis Tuberculosis and other mycobacterial diseases Weight |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQhBAviG8yBjITEhLIWlLbsc1bQatAGqPiY9qb5TjOVqlLpqZF47_nLnHLMjR44alqfGncu7P9u971d4S8zHhVoDWZq3zBhJaemVHmGA954ULqTd79mHN0oA4P9fGxmV5q9YU1YT09cK-4vdKX4GKGp6XwIhSVAZyFrFE8c0WVqRJ3X0A962Aq5g_g3DMxh5npfK-FXVhhXZBmHAImJganUEfW_-eWfOlMuloveSVp2p1Fk7vkTgSRdNxP_h65Eer75NanmCZ_QCbjmob6tEvuU2y9cBZq6lp63rRLFi7gZbUIFMx11sA0QNFzdzFrKeBXOg9wpf35lk73pw_J98n-t_cfWGyYwLzUuWBappXk2OKrAs1rnxfG6WrkNGAewbkHPFUqXzoRFIQRIQ--gHihCJyXQsAb_ohs1U0dnhAqAejJSsgyLSAEVA4-LMucMhoZ2MtcJiRdK9D6yCaOTS3mtosqdG57nVvQuUWdW5GQ15tbznsqjb8Jv0OrbASRBbu7AL5ho2_Yf_lGQnbRphZ5LmospDlxq7a1Hz8f2bGUCrGd0tcJff0yEHoVhaoGvqZ38c8LoCzkzxpI7gwkYbX64fDav2zcLVoL8AGZ5ABKJuTFZhjvxAq4OjQrlMlyQBKwqSXkce-OG-XwdGRSZWBEDRx1oL3hSD077bjEAcACQobnvlm79O9pXWuc7f9hnKfk9ggXZFeMsUO2lotVeEZu-h_LWbt43i3nX9kySxo priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELegQwgJ8TG-CgMZhITEZC2pndjhBXWoFUhQqgHT3izHcbZKXVKaFo3_nrvEzcjQ9sJT1fjSxr7zffguvyPkdcjzFLnJTG5TJlRkWTIIDeMuTo0LbBLXhzmHn-Vkoo6Okqk_cKt8WeVGJ9aKOistnpHvgYpFtC0wt-8XPxl2jcLsqm-hcZ1sIVKZ6JGt_dFketDmEcD-JT6XGap4rwJtLLE-SDEOgRMTHWtUg_b_q5r_sk0X6yYvJE9rmzS--7-zuUfueG-UDhvxuU-uuWKb3Pzi8-3b5HZzqkebl5UekPGwoK44qasGKPZ0OHUFNRVdlNWKuTP4WC8dBTk4LeGBgINzczarKDjGdO7gSvX7HZ2Opg_Jj_Ho-4ePzHdiYDZSsWAqCvKIY--wHFiqbJwmRuUDo8CZEpxbcNQyaTMjnIT4xMXOphCIpI7zTAj4wh-RXlEW7gmhEXiQUS6iLEghtpQGfiwMjUwUQrtncdQnwYYj2nqYcuyWMdd1uKJi3TBRAxM1MlGLPnnb3rJoMDquIt5HNreECK9dXyiXx9rvVp3ZDPRawoNMWOHSPAHnHqHKeGjSPJRZn7xCIdEIoFFghc6xWVeV_vT1UA-jSKLTKNVlRN8OOkRvPFFewjSt8W9FwGIhMFeHcqdDCWrAdoc3kqa9Gqr0uZj1yct2GO_E0rrClWukCWNwUUBb9snjRr7bxeHBIAlkAiOyI_md1euOFLOTGqQcPGNwveF_dzd75PyxLmXO06sn8YzcGuDeres3dkhvtVy75-SG_bWaVcsXfu__AVTCXuc priority: 102 providerName: ProQuest |
| Title | An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP |
| URI | https://link.springer.com/article/10.1186/s12879-018-3402-4 https://www.ncbi.nlm.nih.gov/pubmed/30290790 https://www.proquest.com/docview/2122504727 https://www.proquest.com/docview/2116847200 https://pubmed.ncbi.nlm.nih.gov/PMC6173927 https://doaj.org/article/dcd880930d4c4ebf981b570331abf17d |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature Link Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYhhAv4xsCowoICQkULamd2OGtm1oxiZWog6o8WY7jbJW6ZGraafz33LlJIIMhwUuixOd83Jd_zl3OhLwJaJ6iND2V69RjItRe3A-UR02UKuPrOLIfc6af-HgsZrM4qf_jrpps9yYkaT21NWsR7VfgSTnm9giPwqTHY1tkB0Y7gdY4OZm2oQMY8uI6fPnHbp0ByNbp_90b_zIcXU-VvBYvtcPQ6N5_vcB9slujTnewUZMH5JYpHpI7x3Vc_REZDQrXFGc2G8DFtRrOTeGqyr0oq5VnrmC3XhoX5HtewsODZBbqal65AHjdhYEz1fcPbjJMHpOvo-GXw49evcKCp0MRMU-Efh5SXBMsB1EJHaWxEnlfCQBJjFINACzjOlPMcJh3mMjoFCYYqaE0YwwO6BOyXZSFeUbcEJBhmLMw81OYM3IFFwsCxWOBJduzKHSI37Bd6rr8OK6CsZB2GiIiueGPBP5I5I9kDnnXdrnY1N74G_EByrIlxLLZ9kS5PJW1FcpMZ-CvYupnTDOT5qA9KZYgo4FK84BnDnmNmiCxMEaBmTenal1V8ujzVA7CkCMY5OImopNJh-htTZSX8Jpa1X87ALOw4FaHcq9DCeatu82NVsravVQS8AaWngPs6ZBXbTP2xJS5wpRrpAkigB7gBR3ydKPELXOo3499HkML76h3h3vdlmJ-ZouPA-IFSA33fd8o-c_HulE4z_-J-gW520crsWkae2R7tVybl-S2vlzNq2WPbPEZt1sBW3EY9MjOwXCcTHr2ewocJUfHybee9Qo_AEyNVS0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3rb9MwELdGhwAJ8RivwgCDQEigaEnsJA4SQgVWrVo7qjGm8ck4jrNV6pLStLD9U_yN3OXRkaHt2z7wqWp8efj88z3s8x0hLxyWRDialkp0ZHHhaSt0HWUx40fK2Dr0i8Wc3X6wtSX29sLhEvldn4XBsMpaJhaCOs40rpGvgYjFbFugbt9PflhYNQp3V-sSGiUsNs3xL3DZ8ne9TzC-L123u77zccOqqgpY2hM-t4RnJx7DOlgJfJ7QfhQqkbhKgGHAGdNgdMSBjhU3Adjaxjc6AqM6MozFnMMfBs-9RJY5gF20yPKwNxh-W-xbgL4Nq71TR_hrOUj_AOORhMXAUbN4Q_sVRQL-VQV_6cLTcZqnNmsLHdi9-b9x7xa5UVnbtFNOj9tkyaQr5MqgiidYIdfLVUtaHsa6Q7qdlJr0oIiKoFiz4tCkVOV0kuUzyxzBz3xqKOD8MAMGAELH6miUUzD86djAlfz4LR2uD--SrxfSq3uklWapeUCoBxayl3AvtiPwnQMFD3McFYQCU9fHvtcmdo0Aqas07FgNZCwLd0z4sgSNBNBIBI3kbfJ6ccukzEFyHvEHhNWCENOHFxey6b6spJGMdQxyO2R2zDU3URKC84Kp2JijosQJ4jZ5jqCUmCAkxQikfTXPc9n7vCs7nhegURyIs4i-bDeIXlVESQbd1Ko69QHMwsRjDcrVBiWIOd1srpEtKzGbyxNYt8mzRTPeiaGDqcnmSOP4YIKBNmiT--V8WjCH2W5oByG0BI2Z1uBesyUdHRRJ2MHyB9cC3vumnpMnn3Xm4Dw8vxNPydWNnUFf9ntbm4_INRflRhGrskpas-ncPCaX9c_ZKJ8-qeQOJd8verL-AegevfM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgoImX8Q0ZAwJCQmKKltR27PBWYBUTo1QMqr1ZjuNslTqnalo0_nvu8gUZDAnxVDW-tPXd-fy7-vI7Ql5ENE_RmoHOTRowyU2QDCIdUBun2oYmias_c6aHYjyWx8fJpOlzWrbV7u2RZP1MA7I0udXeIsvrJS7jvRKiqsA6HxlQSIACdpVcY9gzCNP1o2l3jADbX9IcZf7xtt5mVHH2_x6Zf9maLpZNXjg7rbak0c3_nswtstWgUX9Yu89tcsW6O2TzY3PefpeMhs637rSqEvCxh8OZdb4u_UVRrgJ7Di_rpfXB7mcFTAQsNtfns9IHIOzPLVwpv7_2J_uTe-TraP_L2_dB03khMFzGLJA8zDnFXmE5mFCaOE20zAdaAnhilBoAZpkwmWZWQD5iY2tSSDxSS2nGGLyh98mGK5x9SHwOiJHnjGdhCrmk0PBhUaRFIpHKPYu5R8LWBMo0tOTYHWOuqvRExqrWjwL9KNSPYh551d2yqDk5_ib8Bu3aCSKddnWhWJ6oZnWqzGQQxxIaZswwm-YJgHmkJqORTvNIZB55jl6hkDDDYUXOiV6XpTr4NFVDzgWCRCEvEzr63BN62QjlBUzT6OYpCFAWEnH1JHd6krDsTX-49VDVhJ1SAQ5BSjrApB551g3jnVhK52yxRpkoBkgC0dEjD2qH7pRDw0ESigRGRM_Ve9rrj7jZaUVKDkgYoDZ8727r8D9_1qXG2f4n6adkc_JupA4Pxh8ekRsDXDBVJccO2Vgt1_YxuW6-rWbl8kkVBH4AdopaGA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+enhanced+regimen+as+post-exposure+chemoprophylaxis+for+leprosy%3A+PEP&rft.jtitle=BMC+infectious+diseases&rft.au=Mieras%2C+Liesbeth+F&rft.au=Taal%2C+Anna+T&rft.au=van+Brakel%2C+Wim+H&rft.au=Cambau%2C+Emmanuelle&rft.date=2018-10-05&rft.eissn=1471-2334&rft.volume=18&rft.issue=1&rft.spage=506&rft_id=info:doi/10.1186%2Fs12879-018-3402-4&rft_id=info%3Apmid%2F30290790&rft.externalDocID=30290790 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |